SYNBIOMATICA

Research

The US patent office finds two Halozyme patents unpatentable over under-the-skin Keytruda

KEYTRUDA IS an antibody cancer drug that is usually given by a drip into a vein. A version called Keytruda Qlex, approved by America's Food and Drug Administration in September 2025, is injected under the skin, so the dose does not have to be infused into a vein.

The under-the-skin shot works because it includes an enzyme that briefly breaks down a gel-like substance, hyaluronic acid, in the tissue beneath the skin, so a large volume of the drug can spread and be absorbed. An enzyme that does this is a hyaluronidase. Chosunbiz reports that the enzyme in Qlex is ALT-B4, developed by the Korean company Alteogen. Halozyme, Inc. makes a rival hyaluronidase technology and says Qlex infringes its patents on modified forms of PH20, a human hyaluronidase.

Merck Sharp & Dohme, the American firm known as Merck, began filing challenges to those patents in November 2024. Halozyme sued Merck for patent infringement in federal court in New Jersey in April 2025, Chosunbiz reports.

The Patent Trial and Appeal Board is a tribunal inside the US patent office. In a procedure called post-grant review, a petitioner may ask the office, within nine months after a patent is issued, to decide whether claims in that new patent should have been granted. At the end of the review the board issues a final written decision, which can cancel the claims if they are found unpatentable.

On November 18th 2026 the board, in opinions by Administrative Patent Judge Susan L. C. Mitchell, joined by Judges Jeffrey N. Fredman and Cynthia M. Hardman, found all remaining challenged claims unpatentable in Halozyme patents 12,077,791 and 12,195,773. Unified Patents records both reviews as ended with final written decisions on that date. Chosunbiz reports that all 14 post-grant reviews the board agreed to hear in this dispute have now ended in Merck's favor. The reviews were opened on November 19th 2025, and the board heard argument on July 23rd 2026.

Both patents claim large families of modified PH20 proteins. Proteins are chains of amino acids. The first patent requires a specified change at position 309 in that chain, chosen from ten allowed amino acids. The second requires a change at position 320 to one of three amino acids, and allows up to 19 further changes. Merck had challenged claims 1 to 10 of the first patent and claims 1 to 15 of the second. Halozyme formally surrendered claims 4 and 5 of the first patent and claim 4 of the second, so the board decided the rest.

In plain terms, the board found that Halozyme had claimed a huge set of possible enzyme variants but had not shown that it actually possessed them, and had not taught others how to make and use them without excessive trial and error. Those two requirements are known as written description and enablement. The board found that both patents failed each of those requirements. The board relied on expert estimates that the claims covered from 10 to the 49th to 10 to the 60th distinct protein variants in the first patent, and 10 to the 57th in the second. The patents provided examples of a single change to the enzyme but essentially no examples of several changes at once. The computational techniques available in December 2012, the board wrote, "could not be used to reasonably predict the effect of five or more amino acid changes on protein structure and activity."

Merck also argued, for most claims of the second patent, that the invention would have been obvious from earlier published work, meaning a skilled person would have had reason to make the same change. That argument failed. The board found that "Petitioner has not shown by a preponderance of the evidence" that the cited combination demonstrated obviousness. Merck did not argue obviousness against the first patent.

A party that wants a court to review a final written decision must follow the patent office's appeal-notice rules, and such an appeal goes to the US Court of Appeals for the Federal Circuit. Halozyme's infringement case against Merck in federal court in New Jersey continues. As of November 17th, according to postgrantproceeding.com, Halozyme had asked the patent office's director to review four October decisions in the same dispute, and those requests were still pending. Three separate Merck challenges to older Halozyme patents, a different procedure known as inter partes review, were opened on September 9th 2026, according to Unified Patents, and are still pending.

Sources

  1. PTAB Final Written Decision, PGR2025-00050, Merck Sharp & Dohme LLC v. Halozyme,
  2. PTAB Final Written Decision, PGR2025-00053, Merck Sharp & Dohme LLC v. Halozyme,
  3. Unified Patents case record for PGR2025-00050, patent 12,077,791, Final Written
  4. Unified Patents case record for PGR2025-00053, patent 12,195,773, Final Written
  5. Unified Patents PTAB case list for petitioner Merck Sharp & Dohme, used with the
  6. Unified Patents PTAB case list for patent owner Halozyme Inc
  7. Unified Patents case record for IPR2026-00312, Merck Sharp & Dohme LLC v. Halozy
  8. Unified Patents case record for IPR2026-00313, Pending - Instituted, institution
  9. Unified Patents case record for IPR2026-00314, Pending - Instituted, institution
  10. Chosunbiz, Merck wins all 14 U.S. patent reviews against Halozyme, November 19,
  11. postgrantproceeding.com, Four post-grant reviews: section 112(a) won, obviousnes
  12. 35 U.S.C. section 321(c), nine-month window for a post-grant review petition
  13. 35 U.S.C. section 329, appeal of a post-grant review final written decision
  14. Unified Patents record for PGR2025-00046, patent 12,091,692, Final Written Decis